webinar register page

Webinar banner
ICER | Midwest CEPAC: Nadofaragene Firadenovec and Oportuzumab Monatox for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
ICER Public Meeting to Deliberate on the Comparative Clinical and Cost Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer.

Nov 20, 2020 10:00 AM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

By registering, I agree to the Privacy Statement and Terms of Service.

Register